[go: up one dir, main page]

MX2019009640A - Ingrediente activo farmaceutico y uso del mismo, en particular, para la prevencion y el tratamiento de trastornos metabolicos en humanos y animales. - Google Patents

Ingrediente activo farmaceutico y uso del mismo, en particular, para la prevencion y el tratamiento de trastornos metabolicos en humanos y animales.

Info

Publication number
MX2019009640A
MX2019009640A MX2019009640A MX2019009640A MX2019009640A MX 2019009640 A MX2019009640 A MX 2019009640A MX 2019009640 A MX2019009640 A MX 2019009640A MX 2019009640 A MX2019009640 A MX 2019009640A MX 2019009640 A MX2019009640 A MX 2019009640A
Authority
MX
Mexico
Prior art keywords
prevention
treatment
active pharmaceutical
pharmaceutical ingredient
humans
Prior art date
Application number
MX2019009640A
Other languages
English (en)
Other versions
MX380833B (es
Inventor
MAUGARD Thierry
Sirvent Pascal
PELTIER Sébastien
Chavanelle Vivien
LE JOUBIOUX Florian
Original Assignee
Valbiotis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valbiotis filed Critical Valbiotis
Publication of MX2019009640A publication Critical patent/MX2019009640A/es
Publication of MX380833B publication Critical patent/MX380833B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

La invención se refiere a un ingrediente farmacéutico activo que consiste exclusivamente en la combinación de ácido (1S,3R,4R,5R)-3-{[(2E)-3-(3,4-)dihidroxifenil)-2-propenoil]oxi}-1 ,4,5- trihidroxiciclohexanocarboxílico y metil (2S,3E,4S)-4-{2-[2-(3,4-dihidroxifenil)etoxi]-2-oxoetil}-3- etilideno-2-(ß-D-glucopiranosiloxi)-3,4-dihidro-2H-piran-5-carbox ilato para uso como medicamento o producto veterinario, particularmente en la prevención y/o el tratamiento de trastornos patológicos del metabolismo de carbohidratos y/o lípidos.
MX2019009640A 2017-02-16 2018-02-13 Ingrediente activo farmacéutico y uso del mismo, en particular, para la prevención y el tratamiento de trastornos metabólicos en humanos y animales. MX380833B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1770144A FR3062795B1 (fr) 2017-02-16 2017-02-16 Principe actif pharmaceutique et utilisation en particulier dans la prevention et le traitement des dereglements metaboliques chez l'homme et l'animal.
PCT/EP2018/053520 WO2018149812A1 (fr) 2017-02-16 2018-02-13 Principe actif pharmaceutique et utilisation en particulier dans la prevention et le traitement des dereglements metaboliques chez l'homme et l'animal

Publications (2)

Publication Number Publication Date
MX2019009640A true MX2019009640A (es) 2019-10-02
MX380833B MX380833B (es) 2025-03-11

Family

ID=58645316

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009640A MX380833B (es) 2017-02-16 2018-02-13 Ingrediente activo farmacéutico y uso del mismo, en particular, para la prevención y el tratamiento de trastornos metabólicos en humanos y animales.

Country Status (18)

Country Link
US (1) US11191744B2 (es)
EP (1) EP3582767B1 (es)
JP (2) JP2020509998A (es)
KR (1) KR20190130572A (es)
CN (1) CN110520120A (es)
AU (1) AU2018221616A1 (es)
BR (1) BR112019016945A2 (es)
CA (1) CA3051789A1 (es)
ES (1) ES2879318T3 (es)
FR (1) FR3062795B1 (es)
IL (1) IL268271A (es)
MA (1) MA47498B1 (es)
MX (1) MX380833B (es)
PL (1) PL3582767T3 (es)
RU (1) RU2759903C2 (es)
SG (1) SG11201906907TA (es)
WO (1) WO2018149812A1 (es)
ZA (1) ZA201905309B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11152221B2 (en) 2019-02-20 2021-10-19 Applied Materials, Inc. Methods and apparatus for metal silicide deposition
IT202100031985A1 (it) * 2021-12-21 2023-06-21 Innbiotec Pharma S R L Composizione farmaceutica a base di glutatione tioestere e oleuropeina per l’uso nel trattamento della steatoepatite non alcolica

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070009620A1 (en) * 2005-07-11 2007-01-11 Yoshinori Aoki Cholesterol regulating agent
JP2007045814A (ja) * 2005-07-11 2007-02-22 Eisai Food Chemical Kk コレステロール調節剤
US20090061031A1 (en) * 2006-07-07 2009-03-05 Sylvia Lee-Huang Compositions and methods for treating obesity, obesity related disorders and for inhibiting the infectivity of human immunodeficiency virus
CA2705785A1 (en) * 2006-11-14 2008-05-22 Saul Yedgar Use of lipid conjugates in the treatment of diseases or disorders of the eye
CN100502854C (zh) * 2007-01-23 2009-06-24 武汉大学 绿原酸在制备抗糖尿病并发症的药中的应用
ITMI20080514A1 (it) * 2008-03-27 2009-09-28 Univ Firenze Uso della oleuropeina e suoi derivati nel trattamento del diabete mellito di tipo 2 e di patologie associate a fenomeni di aggregazione di proteine
RU2451506C1 (ru) * 2011-06-02 2012-05-27 Сергей Юрьевич Лешков Комбинация для лечения сахарного диабета и его осложнений
FR3027228B1 (fr) * 2014-10-20 2016-12-09 Valbiotis Composition comprenant un melange d'extraits vegetaux et utilisation pour agir sur le metabolisme glucidique et/ou lipidique

Also Published As

Publication number Publication date
US20200009101A1 (en) 2020-01-09
RU2019125320A3 (es) 2021-05-20
ES2879318T3 (es) 2021-11-22
WO2018149812A1 (fr) 2018-08-23
JP2022180477A (ja) 2022-12-06
JP2020509998A (ja) 2020-04-02
FR3062795B1 (fr) 2019-06-07
PL3582767T3 (pl) 2021-11-08
ZA201905309B (en) 2020-05-27
AU2018221616A1 (en) 2019-08-08
RU2019125320A (ru) 2021-03-16
EP3582767B1 (fr) 2021-04-07
US11191744B2 (en) 2021-12-07
SG11201906907TA (en) 2019-08-27
KR20190130572A (ko) 2019-11-22
RU2759903C2 (ru) 2021-11-18
CN110520120A (zh) 2019-11-29
CA3051789A1 (fr) 2018-08-23
MA47498B1 (fr) 2021-08-31
IL268271A (en) 2019-09-26
EP3582767A1 (fr) 2019-12-25
BR112019016945A2 (pt) 2020-04-14
FR3062795A1 (fr) 2018-08-17
MX380833B (es) 2025-03-11

Similar Documents

Publication Publication Date Title
ES2524320T3 (es) Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
MX2016000307A (es) Farmaco para el tratamiento de la esteatosis hepatica no alcoholica.
BR112015014372A8 (pt) inibidores de autotaxina, seus usos, e composição e combinação farmacêuticas".
EP4559902A3 (en) Kdm1a inhibitors for the treatment of disease
NZ631100A (en) Soft chewable pharmaceutical products
AR098576A1 (es) Producto farmacéutico
MX357780B (es) Derivados policíclicos, proceso para su preparación y su uso farmacéutico.
BR112015019412A2 (pt) inibidores de bace1
CO2020000240A2 (es) Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico
AR104068A1 (es) Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
BR112015029897A2 (pt) composição sólida para administração oral contendo ácido ibandrônico ou um seu sal farmaceuticamente aceitável e vitamina d e processo para obtenção da referida composição
MX2017011499A (es) Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
MX2022003969A (es) Composiciones degustables que incluyen fenilbutirato de sodio y usos de las mismas.
UY28209A1 (es) Derivados de aminoácidos con cicloalquilo, procedimiento para su preparación y su uso como medicamentos.
MX384072B (es) Compuesto derivado de pirrolo-piridina, metodo para preparar el mismo y composicion farmaceutica que contiene el mismo como ingrediente activo para la prevencion o el tratamiento de enfermedades relacionadas con la proteina cinasa.
MX2019009640A (es) Ingrediente activo farmaceutico y uso del mismo, en particular, para la prevencion y el tratamiento de trastornos metabolicos en humanos y animales.
CL2018000391A1 (es) Combinaciones farmacéuticas y su uso
EP2722322A4 (en) 1,3-DI-OXO-INDEN DERIVATIVE, PHARMACEUTICALLY ALLOWED SALT AND OPTICAL ISOMER THEREOF, METHOD OF MANUFACTURING THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THIS DERIVATIVE AS AN ANTIVIRAL ACTIVE SUBSTANCE
PA8596701A1 (es) Derivados de aminoacidos sustituidos con cicloalquilo, procedimiento para su preparacion y su uso como medicamentos
MX2020004105A (es) Formulacion farmaceutica.
EP2873419A4 (en) PHARMACEUTICAL COMPOSITION WITH AZATHIOPRINE AS ACTIVE AGENT FOR PREVENTION TREATMENT OF BRAIN TUMORS OR TEMODAL RESISTANT GLIOBLASTOMES
EP4023647A4 (en) IMIDAZOPYRIDINL DERIVATIVES AND PHARMACEUTICAL COMPOSITION WITH THEM AS AN ACTIVE SUBSTANCE
SV2017005527A (es) Agente terapéutico para disfunción del lóbulo frontal
BR112015015493A2 (pt) composição farmacêutica que contém um derivado de n-fenilpirazol e de permetrina, uso para a preparação de um medicamento veterinário tópico